| Autor: |
Liu M; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Mirza A; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., McAndrew PC; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Thapaliya A; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Pierrat OA; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Stubbs M; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Hahner T; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Chessum NEA; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Innocenti P; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Caldwell J; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Cheeseman MD; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Bellenie BR; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., van Montfort RLM; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K.; Division of Structural Biology, The Institute of Cancer Research, London SM2 5NG, U.K., Newton GK; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Burke R; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Collins I; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K., Hoelder S; Centre for Cancer Drug Discovery, The Institute of Cancer Research, London SM2 5NG, U.K. |
| Abstrakt: |
High hit rates from initial ligand-observed NMR screening can make it challenging to prioritize which hits to follow up, especially in cases where there are no available crystal structures of these hits bound to the target proteins or other strategies to provide affinity ranking. Here, we report a reproducible, accurate, and versatile quantitative ligand-observed NMR assay, which can determine K d values of fragments in the affinity range of low μM to low mM using transverse relaxation rate R 2 as the observable parameter. In this study, we examined the theory and proposed a mathematical formulation to obtain K d values using non-linear regression analysis. We designed an assay format with automated sample preparation and simplified data analysis. Using tool compounds, we explored the assay reproducibility, accuracy, and detection limits. Finally, we used this assay to triage fragment hits, yielded from fragment screening against the CRBN/DDB1 complex. |
